Skip to content

Aquestive Therapeutics, Inc. AQST Compensation and benefits

Compensation and benefits at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
Viatris logo
ViatrisVTRS
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Absci Corporation logo
Absci CorporationABSI
Precigen logo
PrecigenPGEN
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s compensation and benefits?
Aquestive Therapeutics, Inc. (AQST) reported compensation and benefits of $2.07M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s compensation and benefits changed year-over-year?
Aquestive Therapeutics, Inc.'s compensation and benefits decreased by 5.5% year-over-year, from $2.19M to $2.07M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s compensation and benefits?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s compensation and benefits has grown at a -10.1% compound annual growth rate (CAGR), from $6.33M to $3.71M.